The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference Programs brings together stakeholders across the cancer immunotherapy field to advance the science, discover breakthroughs and educate the world on cancer immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual Meeting & Pre-Conference Programs provides more than 2,700 international leaders from academia, regulatory and government agencies, as well as industry representatives with a multidisciplinary educational and interactive environment focused on improving outcomes for all cancer patients.
Registration is currently open for the 32nd Annual Meeting & Pre-Conference Programs!
Scheduled for November 8-12 in National Harbor, Md., the event will take place at the Gaylord National Hotel & Convention Center. Register today to join us at the premier destination for scientific exchange, education and networking in the cancer immunotherapy field!
Click on the titles below to view each program's schedule, purpose, educational objectives and world-renowned faculty.
Concurrent Program I: Primer on Tumor Immunology and Cancer Immunotherapy™
Concurrent Program II: Workshop on Single Cell Techniques in Immunology and Cancer Immunotherapy 8 a.m. – 5 p.m.
Looking for archived SITC Annual Meeting content? Visit past conference websites below:
The following are future scheduled dates and locations for the society's Annual Meeting & Pre-Conference Programs:
Nov. 7-11, 2018 at the Walter E. Washington Convention CenterWashington, District of Columbia
Nov. 6-10, 2019 at the Gaylord National Hotel & Convention CenterNational Harbor, Maryland
Nov. 11-15, 2020 at the Gaylord National Hotel & Convention CenterNational Harbor, Maryland
Nov. 10-14, 2021 at the Walter E. Washington Convention CenterWashington, District of Columbia
Learn from past delegates why you cannot miss the SITC Annual Meeting & Pre-Conference Programs in the following videos:
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys tumor cells including cancer stem cells is, thus, needed urgently. ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics for neuroblastoma, was previously available in Europe under ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com